PRME
Prime Medicine, Inc.
There isn't enough reported data to score PRME yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
PRME Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRME's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PRME PE Valuation
PRME has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
PRME Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Moderate | |
| Low |
Analysts expect PRME's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PRME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.96 | +$0.48 |
| Q2 2026 | -$1.06 | +$0.50 |
| Q1 2026 | -$1.23 | +$0.38 |
| Q4 2025 | -$1.35 | +$0.30 |
| Q3 2025 | -$1.44 | +$0.62 |
| Q2 2025 | -$1.56 | +$0.61 |
| Q1 2025 | -$1.61 | +$0.57 |
| Q4 2024 | -$1.65 | +$0.53 |
PRME is still losing money, but far less than before: $0.96 per share over the past year, against $3.02 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over PRME on earnings quality, reporting a profit while its opponent remains loss making.
PRME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2M | +244% |
| Q4 2025 | $838K | -62% |
| Q3 2025 | $1.2M | +486% |
| Q1 2025 | $1.5M | +146% |
PRME has the stronger quarterly revenue trend. Revenue is up 190% for PRME versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -948% | +3458 points |
| Q4 2025 | -5800% | -3775 points |
| Q3 2025 | -4406% | +21542 points |
| Q2 2025 | -4787% | N/A |
| Q1 2025 | -3603% | +4576 points |
| Q4 2024 | -2026% | N/A |
| Q3 2024 | -25948% | N/A |
| Q1 2024 | -8180% | N/A |
PRME's operating margin was −948% last quarter, up 2656 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over PRME on profitability, with a higher operating margin.
PRME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37M | -$1.7M |
| Q2 2026 | -$41.1M | +$1.9M |
| Q1 2026 | -$42.9M | +$8.4M |
| Q4 2025 | -$37.5M | -360% |
| Q3 2025 | -$35.3M | -$8.1M |
| Q2 2025 | -$43M | +$4.4M |
| Q1 2025 | -$51.3M | +$18.8M |
| Q4 2024 | $14.5M | +$60.2M |
PRME has burned cash in almost every quarter: −$159M over the past year, against −$115M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over PRME on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +632K shares |
| 1 year | +11% | +17.4M shares |
| 3 years | +97% | +87.4M shares |
| 5 years | +86% | +82.1M shares |
PRME has 178M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PRME on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PRME Net Leverage
PRME's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PRME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.1 | Neutral |
| Stochastic | 53.0 | Neutral |
PRME's weekly RSI is 53 (neutral) and its Stochastic is 53 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PRME PE vs Healthcare Sector
PRME has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
PRME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 2.9% above |
| 20 week MA | $3.50 | 11% above |
| 50 week MA | $3.54 | 9.9% above |
| 100 week MA | $3.31 | 18% above |
| 200 week MA | $6.15 | 37% below |
PRME has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 37% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
PRME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $15.8 | $17.8 | +13% |
| 2023 | $17.8 | $8.86 | -50% |
| 2024 | $8.86 | $2.90 | -67% |
| 2025 | $2.90 | $3.50 | +21% |
| 2026 YTD | $3.50 | $3.89 | +11% |
PRME has finished lower in two of the last four years. It's up 11% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PRME on returns for 2026, with the stronger performance.